Taysha Gene Therapies Cost of Goods Sold 2020-2024 | TSHA
Taysha Gene Therapies cost of goods sold from 2020 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
Taysha Gene Therapies Annual Cost of Goods Sold (Millions of US $) |
2023 |
$ |
2022 |
$ |
2021 |
$ |
2020 |
$ |
2019 |
$ |
Taysha Gene Therapies Quarterly Cost of Goods Sold (Millions of US $) |
2024-06-30 |
|
2024-03-31 |
|
2023-12-31 |
|
2023-09-30 |
|
2023-06-30 |
|
2023-03-31 |
|
2022-12-31 |
|
2022-09-30 |
|
2022-06-30 |
|
2022-03-31 |
|
2021-12-31 |
|
2021-09-30 |
|
2021-06-30 |
|
2021-03-31 |
|
2020-12-31 |
|
2020-09-30 |
|
2020-06-30 |
|
2020-03-31 |
|
2019-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Generic Drugs |
$0.490B |
$0.015B |
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|